BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25143329)

  • 1. The effect of renin-angiotensin system blockade on renal protection in chronic kidney disease patients with hyperkalemia.
    Lee JH; Kwon YE; Park JT; Lee MJ; Oh HJ; Han SH; Kang SW; Choi KH; Yoo TH
    J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):491-7. PubMed ID: 25143329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Underprescription of renin-angiotensin system blockers in moderate to severe chronic kidney disease.
    Shirazian S; Grant CD; Mujeeb S; Sharif S; Kumari P; Bhagat M; Mattana J
    Am J Med Sci; 2015 Jun; 349(6):510-5. PubMed ID: 26030613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Renin-Angiotensin System Blockade on Renal Outcomes and Mortality in Pre-Dialysis Patients with Advanced Chronic Kidney Disease.
    Oh YJ; Kim SM; Shin BC; Kim HL; Chung JH; Kim AJ; Ro H; Chang JH; Lee HH; Chung W; Lee C; Jung JY
    PLoS One; 2017; 12(1):e0170874. PubMed ID: 28122064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
    Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
    PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of ET(A) receptor blockade increases renoprotection provided by renin-angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats.
    Čertíková Chábová V; Vernerová Z; Kujal P; Husková Z; Škaroupková P; Tesař V; Kramer HJ; Kompanowska-Jezierska E; Walkowska A; Sadowski J; Červenka L; Vaněčková I
    Life Sci; 2014 Nov; 118(2):297-305. PubMed ID: 24373834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern?
    Yildirim T; Arici M; Piskinpasa S; Aybal-Kutlugun A; Yilmaz R; Altun B; Erdem Y; Turgan C
    Ren Fail; 2012; 34(9):1095-9. PubMed ID: 22950572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of and risk factors for newly diagnosed hyperkalemia after hospital discharge in non-dialysis-dependent CKD patients treated with RAS inhibitors.
    Saito Y; Yamamoto H; Nakajima H; Takahashi O; Komatsu Y
    PLoS One; 2017; 12(9):e0184402. PubMed ID: 28877239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
    Onuigbo MA; Onuigbo NT
    QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment?
    Caravaca-Fontán F; Valladares J; Díaz-Campillejo R; Barroso S; Luna E; Caravaca F
    Nefrologia (Engl Ed); 2020; 40(1):38-45. PubMed ID: 31196659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting.
    Kurnik D; Vesterman-Landes J; Bialik M; Katzir I; Lomnicky Y; Halkin H; Loebstein R
    Clin Ther; 2011 Apr; 33(4):456-64. PubMed ID: 21635991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
    N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease.
    Garlo KG; Bates DW; Seger DL; Fiskio JM; Charytan DM
    JAMA Netw Open; 2018 Nov; 1(7):e183874. PubMed ID: 30646338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in treatment of hyperkalemia in chronic kidney disease.
    Sarafidis PA; Georgianos PI; Bakris GL
    Expert Opin Pharmacother; 2015; 16(14):2205-15. PubMed ID: 26330193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
    Degli Esposti L; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Santoro A
    G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease.
    Frimodt-Møller M; Høj Nielsen A; Strandgaard S; Kamper AL
    Nephrol Dial Transplant; 2010 Mar; 25(3):842-7. PubMed ID: 19903661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.